



Broad Spectrum Antivirals against Beta-Coronaviruses

Guest Editors:

Dr. Lalit Batra

Regional Biocontainment
Laboratory (RBL), Center for
Predictive Medicine, University of
Louisville, Louisville, KY 40292,
USA

Dr. Divyasha Saxena

Center for Predictive Medicine
(CPM), Clinical Translational
Research Building (CTRB), 505
South Hancock Street, Rm#626A,
Louisville, KY 40222, USA

Deadline for manuscript
submissions:

closed (31 October 2023)

Message from the Guest Editors

Dear Colleagues,

There are several types of coronaviruses, but three highly pathogenic viruses to humans are severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). MERS-CoV and SARS-CoV-2 in particular present a major threat to global public health because of their high mortality and morbidity rates. MERS-CoV mainly infects the lower respiratory airway (via DPP4 receptor), while SARS-CoV-2 mainly the upper respiratory pathways (via ACE2 receptors), but both are associated with severe respiratory distress syndrome in humans. There is an urgent need to look for natural antiviral compounds that are effective against broad coronavirus infection.

Welcome original manuscripts on the evaluation of novel antivirals against the Coronaviridae family, including studies on in vitro infection (live virus infection, possibly Omicron, and new emerging SARS-CoV-2 VOCs or pseudovirus infection), mechanism of antiviral compounds, evaluation against respiratory 3D tissue models, immune-modulation following antiviral treatment, and in vivo efficacy of animal models.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)